Similar articles

• Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.

  Dimova RB, Talal AH. Dimova RB, et al. J Hepatol. 2010 Sep;53(3):418-20. doi: 10.1016/j.jhep.2010.04.014. Epub 2010 May 31. J Hepatol. 2010. PMID: 20561707 No abstract available.
• Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference?

  Sierra F. Sierra F. J Hepatol. 2007 Feb;46(2):349; author reply 349-50. doi: 10.1016/j.jhep.2006.11.004. Epub 2006 Nov 27. J Hepatol. 2007. PMID: 17161495 No abstract available.
• Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

  Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M. Lukasiewicz E, et al. Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505. Hepatology. 2007. PMID: 17187414 No abstract available.
• Peginterferon and ribavirin for chronic hepatitis C.

  Hoofnagle JH, Seeff LB. Hoofnagle JH, et al. N Engl J Med. 2006 Dec 7;355(23):2444-51. doi: 10.1056/NEJMct061675. N Engl J Med. 2006. PMID: 17151366 Review. No abstract available.
• [Treatment of chronic hepatitis C].

  Fehér J, Lengyel G. Fehér J, et al. Orv Hetil. 2004 May 16;145(20):1065-7. Orv Hetil. 2004. PMID: 15202329 Review. Hungarian. No abstract available.